Grit Bio

Grit Bio is a late-stage biopharmaceutical company developing next-generation T-cell therapies for cancer and autoimmune disease, with headquarters in Beijing, a research centre in Shanghai and a GMP manufacturing base in Suzhou. Its pipeline includes GT101, an autologous tumour-infiltrating lymphocyte (TIL) therapy in pivotal development, GT201, a TIL therapy expressing membrane-bound IL-15, CAR-T and CAR-iNKT candidates and neoantigen cancer vaccines. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06241781 (phase 2, Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent...), NCT06948981 (phase 1/2, GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Ma...) and NCT06144671 (phase 1/2, Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.